

**GRANT OF EMPLOYEE SHARE OPTIONS AND SHARE AWARDS PURSUANT TO THE SMG SHARE OPTION SCHEME AND THE SMG SHARE PLAN**

*Unless otherwise specified herein or where the context otherwise requires, capitalised terms used in this announcement shall have the same meaning as used in the Circular dated 15 April 2014 as the case may be.*

The Board of Directors (the “**Board**”) of Singapore Medical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to announce that, on 30 April 2018, the Company has granted 5,320,000 Options and 336,000 Awards to eligible persons under the SMG Share Option Scheme and SMG Share Plan amounting to 1.14% and 0.07% of the existing issued share capital of the Company respectively. Pursuant to Rule 704(32) of the SGX-ST Listing Manual Section B: Rules of Catalyst, the details of the grant of the Share Options and Share Award are disclosed as follows:

		<b>Grant of Options</b>
1	Date of Grant	30 April 2018
2	Exercise Price of Options granted <sup>1</sup>	S\$0.493
3	Number of Options granted	3,700,000 Options to a director, Dr Beng Teck Liang, (the “Director Options”) and 1,620,000 to other employees (the “Remaining Options”). The Director Options and the Remaining Options, collectively the Options.
4	Market price of the Company’s Shares on the Date of Grant	S\$0.50
5	Number of Options granted to each Director and Controlling Shareholder, if any	3,700,000
6	Validity period of the Options	5 years from Date of Grant
7	Exercise Period of the Director Options	<p>The Director Options shall only be exercised after the first anniversary of the Date of the Options subject to the following:</p> <ul style="list-style-type: none"> <li>- the option over up to 25% of the Shares comprised in the Director Option(s) may be exercised after the first anniversary of the Date of Grant of the Option(s);</li> <li>- the option over up to 50% of the Shares comprised in the Director Option(s) may be exercised after the second anniversary of the Date of Grant of the Option(s);</li> <li>- the option over up to 75% of the Shares comprised in the Director Option(s) may be exercised after the third anniversary of the Date of Grant of the Option(s); and</li> <li>- the option over all of the Shares comprised in the Director Option(s) may be exercised after the fourth anniversary of the Date of Grant of the Option(s),</li> </ul> <p>provided always that Director Options shall be exercised before the fifth anniversary of the relevant Date of Grant or such earlier date as may be determined by the Committee, failing which all unexercised Options shall immediately lapse and become null and void and the Option Holder shall have no claim against the Company.</p>

8	Exercise Period of the Remaining Options	<p>Other than the Director Options, all the other Options shall only be exercised after the first anniversary of the Date of Grant of the Option(s) subject to the following:</p> <ul style="list-style-type: none"> <li>- the option over up to one third only of the Shares comprised in the Option(s) may be exercised after the first anniversary of the Date of Grant of the Option(s);</li> <li>- the option over up to two thirds only of the Shares comprised in the Option(s) may be exercised after the second anniversary of the Date of Grant of the Option(s); and</li> <li>- the option over all of the Shares comprised in the Option(s) may be exercised after the third anniversary of the Date of Grant of the Option(s),</li> </ul> <p>provided always that Options shall be exercised before the fifth anniversary of the relevant Date of Grant or such earlier date as may be determined by the Committee, failing which all unexercised Options shall immediately lapse and become null and void and the Option Holder shall have no claim against the Company.</p>
---	--	--

<sup>1</sup> The exercise price is equal to the average of the closing price of the Company's shares on the SGX-ST over the 5 consecutive trading days immediately preceding the date of grant.

		<b>Grant of Awards</b>
1	Date of Grant	30 April 2018
2	Number of Shares granted to each Director and Controlling Shareholder (the "Award")	336,000 <sup>2</sup> Shares to a Director, Dr Beng Teck Liang
3	Market price of the Company's Shares on the Date of Grant	S\$0.50
4	Vesting period of the Shares	<p>The Shares granted will be released in accordance to the following schedule upon achieving the performance target:</p> <ul style="list-style-type: none"> <li>- the first tranche equivalent to 50% of the Shares awarded will be realised at the second anniversary of the Date of Grant; and</li> <li>- the second tranche equivalent to the remaining 50% of the Shares awarded will be released at the third anniversary of the Date of Grant.</li> </ul>

<sup>2</sup> This represents the initial number of Shares (the "Initial Award") awarded on the Date of Grant. The Initial Award will be adjusted, at the second anniversary and third anniversary of the Date of Grant for the first and second tranche respectively, by multiplying the higher of: (i) accumulated dividend yield; or (ii) 3% per annum on a compounded basis for the respective Performance Period.

### **By Order of the Board**

Dr Beng Teck Liang  
Executive Director and Chief Executive Officer

30 April 2018

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "**Sponsor**"), for compliance with the relevant rules of the SGX-ST, this being the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not independently verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place #09-01, Singapore Land Tower, Singapore 048623, Telephone: +65 6337 5115.*